Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 18/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 17/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 16/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401511 | 0.88 | CACNA1G (0.43) | CACNA1ICACNA1GCACNA1H | |
| SCHEMBL13744955 | 0.79 | CLPP (0.44) | CACNA1ICACNA1GCACNA1H | |
| SCHEMBL13745014 | 0.79 | CLPP (0.53) | — | |
| SCHEMBL14629510 | 0.78 | CACNA1G (0.42) | CACNA1ICACNA1GCACNA1HCYP3A4 | |
| SCHEMBL747322 | 0.76 | CLPP (0.56) | CYP3A4 | |
| SCHEMBL763148 | 0.76 | CLPP (0.47) | CACNA1ICACNA1GCACNA1HCYP3A4 | |
| SCHEMBL744660 | 0.76 | CACNA1G (0.46) | CACNA1ICACNA1GCACNA1HMEN1KMT2A | |
| SCHEMBL14629508 | 0.75 | ALDH1A1 (0.44) | CACNA1ICACNA1GCACNA1HKMT2ACYP3A4 | |
| SCHEMBL14620323 | 0.75 | CACNA1G (0.43) | CACNA1ICACNA1GCACNA1HMEN1KMT2A | |
| SCHEMBL747317 | 0.75 | CLPP (0.49) | CACNA1ICACNA1GCACNA1HCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8318738-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8106049-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-01 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20110257185-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-10-20 | — | — | US | disclosed |
| US-7932384-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-04-26 | — | — | US | disclosed |
| EP-1660502-A2 | MODULATION OF ß-CATENIN/TCF ACTIVATED TRANSCRIPTION | Choongwae Pharma Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| US-20060084655-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2006-04-20 | — | — | US | disclosed |
| EP-1611130-A2 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Choongwae Pharma Corporation (KR) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005116032-A2 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2005-12-08 | — | — | WO | disclosed |
| US-20050059628-A1 | Modulation of beta-catenin/TCF-activated transcription | CHOONGWAE PHARMA CORPORATION (KR) | 2005-03-17 | — | — | US | disclosed |
| WO-2005021025-A2 | MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION | CHOONGWAE PHARMA CORPORATION (KR) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004093828-A2 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2004-11-04 | — | — | WO | disclosed |
| EP-1444235-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Choongwae Pharma Corporation (KR) | 2004-08-11 | — | — | EP | disclosed |
| US-20040072831-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2004-04-15 | — | — | US | disclosed |
| WO-2003031448-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084655-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CACNA1I 4791/4885CACNA1G 4620/4885CACNA1H 4542/4885 |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CACNA1I 4791/4885CACNA1G 4620/4885CACNA1H 4542/4885 |
| US-20110257185-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CACNA1I 4791/4885CACNA1G 4620/4885CACNA1H 4542/4885 |
| US-20050059628-A1 | Modulation of beta-catenin/TCF-activated transcription | TCF4, TCF7, TCF7L2 | CACNA1I 3880/4885CACNA1G 3385/4885CACNA1H 3371/4885 |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CACNA1I 4791/4885CACNA1G 4620/4885CACNA1H 4542/4885 |
| US-20040072831-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CACNA1I 4784/4885CACNA1G 4606/4885CACNA1H 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.